Abstract
PD(L)1 inhibitor have shown efficacy for limited sub population of patients (pts) with HER2 negative metastatic breast cancer (MBC). The main predictive marker of efficacy to date are the absence of ER and PR receptor, and pdl1 positivity by IHC. We investigated copy number alteration (CNA) of the PDL1 gene (also named CD274) located at 9p24.1 in the SAFIR02 Breast Immuno randomized phase II trial (NCT02299999).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
